Relay Therapeutics discloses new genetic disease and oncology programs
June 6, 2024
Relay Therapeutics Inc. has disclosed three new programs from its existing preclinical pipeline, including two novel programs from its genetic disease portfolio and a potentially first-in-class NRAS-selective inhibitor.